The Company’s Fully Enzymatic Synthesis™ technology overcomes limitations of length constraints and sequence complexity to deliver the exact sequences customers want
SAN DIEGO, May 16, 2023 – Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced it has shipped enzymatically synthesized oligonucleotides to its sixth customer using the Company’s proprietary Fully Enzymatic Synthesis (FES™) technology. Just three months ago Molecular Assemblies fulfilled its first order in its Key Customer Program, which includes top biotechnology, academic, and synthetic biology researchers.
“Molecular Assemblies was founded with a vision to deliver long, pure oligonucleotides that power new breakthroughs in applications, such as CRISPR, next generation sequencing, and the assembly of genes for numerous human health and synthetic biology applications,” J. Kamdar, President and CEO of Molecular Assemblies. “That vision is now reality with our first placements of enzymatically synthesized oligos in customer’s hands.”
While CRISPR has revolutionized the field of gene editing, one of the largest bottlenecks is the availability of desired sequences required to make increasingly advanced edits. Current DNA synthesis technologies limit the types of gene editing experiments customers can design, due to length constraints and/or sequence complexity. Enzymatic DNA synthesis can generate long, pure single-stranded oligonucleotides, which are a central component for CRISPR gene editing and many other tools used in research discovery, therapeutic development, and protein engineering.
“Feedback from several of our first Key Customer orders have come back extremely positively. Those projects include novel uses in CRISPR gene editing knock-ins enabled by our early access oligonucleotides,” said Phil Paik, Ph.D., Chief Technology Officer of Molecular Assemblies. “We are scaling our manufacturing capacity to fulfill the significant demand we’ve seen and will share more details of these collaborations over the course of the next few months starting with SynBioBeta.”
Presentations at SynBioBeta 2023
Title: DNA Synthesis: The Next Generation
- Day: Wednesday, May 24
- Time: 2:45pm – 3:30pm PT
- Type: Breakout Session
- Speakers: Phil Paik, Ph.D., Chief Technology Officer, Molecular Assemblies, and Steve Bischoff, Ph.D., Founder and Chief Scientific Officer, NovoHelix
Title: How Can We Leverage SynBio’s Full Stack for Human Health?
- Day: Thursday, May 25
- Time: 5:00pm – 5:30pm PT
- Type: Main Stage Panel
- Panelist: Michael J. Kamdar, President and CEO, Molecular Assemblies
Molecular Assemblies is co-hosting the Welcome Party and Dinner on Tuesday, May 23, from 6:30pm – 8:30pm PT. Find our team members at these events and at booth #55 throughout the conference to learn more about FES technology and our Key Customer Program.
About MAI’s Key Customer Program
Molecular Assemblies’ Key Customer Program provides select researchers priority access to long, custom oligonucleotides synthesized with the Company’s FES technology. This program is expected to enable customers to accelerate their research in CRISPR gene editing as well as a variety of other applications requiring long oligonucleotides. Key Customers will also be able to provide feedback to shape the future of enzymatic DNA synthesis.
About Molecular Assemblies
Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented Fully Enzymatic Synthesis™ (or FES™), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego.
Company: Ben Johnson, Director of Product Marketing, firstname.lastname@example.org
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., email@example.com, +1.858.344.8091